Skip to main content

BioFocus' 2008 Revenues Increase 16 Percent

NEW YORK (GenomeWeb News) – BioFocus DPI, the drug discovery products and services division of Belgian firm Galapagos, brought in revenues of €56.4 million ($71.7 million) for full-year 2008, the firm announced today.

The division's revenues were up 16 percent from the year before and included €10.9 million from inter-company revenues eliminated in a consolidation of operations. During the year, BioFocus sold its San Diego operations to ChemVentures.

In addition, in August 2008, Galapagos acquired the drug discovery services assets of Sareum Holdings and integrated those assets into BioFocus.

BioFocus' profit for 2008 was €3.4 million compared to a loss of €3.9 million in 2007.

Overall, Galapagos' revenues rose 17 percent to €77 million for 2008. Its net loss declined 33 percent to €14.6 million, or €.69 per share, from €21.9 million, or €1.06 per share, for 2007. The firm said the results include a €2.6 million charge related to the divestiture of BioFocus' San Diego operations. But it also included a €4.1 million tax credit associated with its operations in Paris.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.